Brief Description
JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.
Estimated Enrollment
75 patients
Estimated End Date
2026
Trial is for people with
Focal Segmental Glomerulosclerosis or clinically diagnosed HTN-CKD
Study Goal
The goal of JUSTICE clinical trial is to determine whether inhibition of APOL1 protein production by baricitinib would slow down ...
What is involved for the patient?
Participants will be randomized to receive baricitinib or placebo control. Urine and a small blood sample will be collected monthly to ...